Results Among the WATCH cohort, 37.7% (182/478) completed trials with either OMA or MEPO. Nearly two-thirds were with OMA (63.7%; 116/182) and the rest were with MEPO (36.3%; 66/182). Eleven from OMA analysis and four from MEPO analysis were excluded due to missing outcome data.